Clinical Guidelines

MENU

Supplement: Sample reports

Supplement: Sample reports

GUIDELINE UPDATES - This guideline was last updated 7/1/2022

Sample cervical screening reports

CERVICAL SCREENINGLOW RISK FOR SIGNIFICANT CERVICAL ABNORMALITY
SPECIMENCervical – ThinPrep
TEST RESULTS

PCR for Oncogenic HPV and genotype:

  • HPV 16 – Not detected
  • HPV 18 – Not detected
  • HPV (not 16/18) – Not detected
RECOMMENDATIONRescreen in five years.


CERVICAL SCREENINGUNSATISFACTORY
SPECIMENCervical – SurePath
TEST RESULTSPCR for Oncogenic HPV and genotype: Unsatisfactory
RECOMMENDATIONRetest within six weeks.


CERVICAL SCREENINGUNSATISFACTORY
SPECIMENCervical – ThinPrep
TEST RESULTS

PCR for Oncogenic HPV and genotype:

  • HPV 16 – Not detected
  • HPV 18 – Not detected
  • HPV (not 16/18) – Detected

Liquid Based Cytology (LBC), Image assisted:
Unsatisfactory

RECOMMENDATIONRepeat screening test in six weeks.


CERVICAL SCREENINGINTERMEDIATE RISK FOR SIGNIFICANT CERVICAL ABNORMALITY
SPECIMENCervical – SurePath
TEST RESULTS

PCR for Oncogenic HPV and genotype:

  • HPV 16 – Not detected
  • HPV 18 – Not detected
  • HPV (not 16/18) – Detected

Liquid Based Cytology (LBC), Manually Read:
There is no evidence of a squamous intraepithelial lesion or malignancy
Endocervical component: Present

RECOMMENDATIONRepeat test in 12 months.


CERVICAL SCREENINGINTERMEDIATE RISK FOR SIGNIFICANT CERVICAL ABNORMALITY
SPECIMENCervical – SurePath
TEST RESULTS

PCR for Oncogenic HPV and genotype:

  • HPV 16 – Not detected
  • HPV 18 – Not detected
  • HPV (not 16/18) – Detected

Liquid Based Cytology (LBC), Image Assisted:
Low grade intra-epithelial lesion (LSIL)
Endocervical component: Present

RECOMMENDATIONRepeat test in 12 months.


CERVICAL SCREENINGHIGHER RISK FOR SIGNIFICANT CERVICAL ABNORMALITY
SPECIMENCervical – ThinPrep
TEST RESULTS

PCR for Oncogenic HPV and genotype:

  • HPV 16 – Not detected
  • HPV 18 – Detected
  • HPV (not 16/18) – Not detected

Liquid Based Cytology (LBC), Manually Read:
High grade squamous intra-epithelial lesion (HSIL)
Endocervical component: Present

RECOMMENDATIONReferral for Colposcopic assessment.


CERVICAL SCREENINGHIGHER RISK FOR SIGNIFICANT CERVICAL ABNORMALITY
SPECIMENCervical – SurePath
TEST RESULTS

PCR for Oncogenic HPV and genotype:

  • HPV 16 – Detected
  • HPV 18 – Not detected
  • HPV (not 16/18) – Not detected

Liquid Based Cytology (LBC), Manually Read:
Unsatisfactory

RECOMMENDATIONReferral for Colposcopic assessment.


CERVICAL SCREENINGHIGHER RISK FOR SIGNIFICANT CERVICAL ABNORMALITY
SPECIMENCervical – ThinPrep
TEST RESULTS

PCR for Oncogenic HPV and genotype:

  • HPV 16 – Not detected
  • HPV 18 – Not detected
  • HPV (not 16/18) – Detected

Liquid Based Cytology (LBC), Image Assisted:
Possible high grade squamous intra-epithelial lesion (pHSIL)
Endocervical component: Not identified

RECOMMENDATIONReferral for Colposcopic assessment.


CERVICAL SCREENINGHIGHER RISK FOR SIGNIFICANT CERVICAL ABNORMALITY
SPECIMENCervical – SurePath
TEST RESULTS

PCR for Oncogenic HPV and genotype:

  • HPV 16 – Detected
  • HPV 18 – Not detected
  • HPV (not 16/18) – Detected

Liquid Based Cytology (LBC), Manually Read:
High grade squamous intra-epithelial lesion (HSIL)
Endocervical component: Not identified

RECOMMENDATIONReferral for Colposcopic assessment.


CERVICAL SCREENINGHIGHER RISK OF SIGNIFICANT CERVICAL ABNORMALITY
SPECIMENCervical – ThinPrep
TEST RESULTS

PCR for Oncogenic HPV and genotype:

  • HPV 16 – Detected
  • HPV 18 – Not detected
  • HPV (not 16/18) – Not detected

Liquid Based Cytology (LBC), Image Assisted:
There is no evidence of a squamous intraepithelial lesion or malignancy
Endocervical component: Present

RECOMMENDATIONReferral for Colposcopic assessment.


CERVICAL SCREENINGHIGHER RISK OF SIGNIFICANT CERVICAL ABNORMALITY
SPECIMENCervical – SurePath
TEST RESULTS

PCR for Oncogenic HPV and genotype:

  • HPV 16 – Not detected
  • HPV 18 – Not detected
  • HPV (not 16/18) – Detected

Liquid Based Cytology (LBC), Manually Read:
There is no evidence of a squamous intraepithelial lesion or malignancy
Endocervical component: Present

RECOMMENDATIONIn view of the previously reported abnormality referral for colposcopic assessment.


CERVICAL SCREENINGHIGHER RISK OF SIGNIFICANT CERVICAL ABNORMALITY
SPECIMENCervical – ThinPrep
TEST RESULTS

PCR for Oncogenic HPV and genotype:

  • HPV 16 – Not detected
  • HPV 18 – Not detected
  • HPV (not 16/18) – Detected

Liquid Based Cytology (LBC), Image Assisted:
Low grade squamous intra-epithelial lesion (LSIL)
Endocervical component: Present

RECOMMENDATIONIn view of the previously reported abnormality referral for colposcopic assessment.


CERVICAL SCREENINGHIGHER RISK OF SIGNIFICANT CERVICAL ABNORMALITY
SPECIMENCervical – SurePath
TEST RESULTS

PCR for Oncogenic HPV and genotype:

  • HPV 16 – Not detected
  • HPV 18 – Not detected
  • HPV (not 16/18) – Detected

Liquid Based Cytology (LBC), Manually Read:
Atypical endocervical cells of undetermined significance
There is no evidence of a squamous intraepithelial lesion or malignancy

RECOMMENDATIONReferral for colposcopic assessment by a gynaecologist with expertise in the evaluation of suspected malignancies or by a gynaecological oncologist.


CERVICAL SCREENINGHIGHER RISK OF SIGNIFICANT CERVICAL ABNORMALITY
SPECIMENCervical – ThinPrep
TEST RESULTS

PCR for Oncogenic HPV and genotype:

  • HPV 16 – Not detected
  • HPV 18 – Detected
  • HPV (not 16/18) – Not detected

Liquid Based Cytology (LBC), Image Assisted:
Possible high grade glandular lesion
The findings suggest possible adenocarcinoma-in-situ

RECOMMENDATIONReferral for colposcopic assessment by a gynaecologist with expertise in the evaluation of suspected malignancies or by a gynaecological oncologist.


CERVICAL SCREENINGHIGHER RISK OF SIGNIFICANT CERVICAL ABNORMALITY
SPECIMENCervical – ThinPrep
TEST RESULTS

PCR for High Risk HPV and genotype:

  • HPV 16 – Detected
  • HPV 18 – Not detected
  • HPV (not 16/18) – Not detected

Liquid Based Cytology (LBC) Image Assisted:
Squamous cell carcinoma
There are abnormal cells that indicate origin from an invasive squamous cell carcinoma Endocervical component: Present

RECOMMENDATIONColposcopy is recommended. Patient should be referred to a gynaecological oncologist or a gynaecological cancer centre for assessment.


CERVICAL SCREENINGHIGHER RISK OF SIGNIFICANT CERVICAL ABNORMALITY
SPECIMENCervical – SurePath
TEST RESULTS

PCR for High Risk HPV and genotype:

  • HPV 16 – Not detected
  • HPV 18 – Detected
  • HPV (not 16/18) – Not detected

Liquid Based Cytology (LBC), Manually Read:
Endocervical adenocarcinoma

RECOMMENDATIONColposcopy is recommended. Patient should be referred to a gynaecological oncologist or a gynaecological cancer centre for assessment.


Sample stand alone LBC reports

SPECIMENCervical – SurePath
TEST RESULTS

Liquid Based Cytology (LBC) Manually Read:


Low grade squamous intra-epithelial lesion (LSIL)
Endocervical component: Present

RECOMMENDATIONThis woman is under specialist management, therefore no management recommendation is made.


SPECIMENCervical – ThinPrep
TEST RESULTS

Liquid Based Cytology (LBC) Image assisted:


High grade squamous intra-epithelial lesion (HSIL)
Endocervical component: Present

RECOMMENDATIONThis woman is under specialist management, therefore no management recommendation is made.

Reports for self-collected samples

CERVICAL SCREENINGLOW RISK OF SIGNIFICANT CERVICAL ABNORMALITY
SPECIMENLower vaginal sample – Self collected
TEST RESULTS

PCR for Oncogenic HPV and genotype:

  • HPV 16 – Not detected
  • HPV 18 – Not detected
  • HPV (not 16/18) – Not detected
RECOMMENDATIONRescreen in five years.


CERVICAL SCREENING
SPECIMENLower vaginal sample – Self collected
TEST RESULTS

PCR for Oncogenic HPV and genotype:

  • HPV 16 – Not detected
  • HPV 18 – Not detected
  • HPV (not 16/18) – Detected
RECOMMENDATIONCollect a cervical sample for LBC within six weeks.


CERVICAL SCREENINGHIGHER RISK OF SIGNIFICANT CERVICAL ABNORMALITY
SPECIMENLower vaginal sample – Self collected
TEST RESULTS

PCR for Oncogenic HPV and genotype:

  • HPV 16 – Detected
  • HPV 18 – Not detected
  • HPV (not 16/18) – Not detected
RECOMMENDATIONRefer for colposcopic assessment. Cervical sample for LBC can be obtained at time of that assessment.
CERVICAL SCREENINGUNSATISFACTORY
SPECIMENLower vaginal sample – Self collected
TEST RESULTSPCR for Oncogenic HPV and genotype: Unsatisfactory
RECOMMENDATIONRetest within six weeks.

Author(s):

WEBSITE UPDATES - This website was last updated 7/1/2022